EGFR and breast carcinoma: Bioluminescence imaging and H&E staining showed that treatment with agomiR-338-3p, a modified miR-338-3p, which was more stable than miR-338-3p mimics, greatly reduced EGFR-mediated breast cancer lung metastasis (Figures 6d and e).